Details for New Drug Application (NDA): 210134
✉ Email this page to a colleague
The generic ingredient in BAQSIMI is glucagon. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the glucagon profile page.
Summary for 210134
Tradename: | BAQSIMI |
Applicant: | Amphastar Pharms Inc |
Ingredient: | glucagon |
Patents: | 3 |
Suppliers and Packaging for NDA: 210134
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
BAQSIMI | glucagon | POWDER;NASAL | 210134 | NDA | Eli Lilly and Company | 0002-6145 | 0002-6145-11 | 1 TUBE in 1 CARTON (0002-6145-11) / 1 BOTTLE, UNIT-DOSE in 1 TUBE (0002-6145-02) / 1 POWDER in 1 BOTTLE, UNIT-DOSE (0002-6145-01) |
BAQSIMI | glucagon | POWDER;NASAL | 210134 | NDA | Eli Lilly and Company | 0002-6145 | 0002-6145-27 | 2 TUBE in 1 CARTON (0002-6145-27) / 1 BOTTLE, UNIT-DOSE in 1 TUBE (0002-6145-02) / 1 POWDER in 1 BOTTLE, UNIT-DOSE (0002-6145-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;NASAL | Strength | 3MG | ||||
Approval Date: | Jul 24, 2019 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 16, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 23, 2039 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 3, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 210134
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Amphastar Pharms Inc | BAQSIMI | glucagon | POWDER;NASAL | 210134-001 | Jul 24, 2019 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription